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Abstract BACKGROUND CONTEXT: The CaO-SiO2-P2O5-B2O3 glass ceramics spacer generates chem-
ical bonding to adjacent bones with high mechanical stability to produce a union with the end plate,
and ultimately stability.
PURPOSE: The authors aimed to compare the clinical efficacy and safety of CaO-SiO2-P2O5-
B2O3 glass ceramics with a titanium cage that is widely used for posterior lumbar interbody fusion
(PLIF) surgery in the clinical field.
STUDY DESIGN/SETTING: This is a prospective, stratified randomized, multicenter, single-
blinded, comparator-controlled non-inferiority trial.
PATIENT SAMPLE: The present study was conducted in four hospitals and enrolled a total of 86
patients between 30 and 80 years of age who required one-level PLIF due to severe spinal stenosis,
spondylolisthesis, or huge disc herniation.
OUTCOME MEASURES: The Oswestry Disability Index (ODI), Short Form-36 Health Survey
(SF-36), and pain visual analog scale (VAS) were assessed before surgery and at 3, 6, and 12 months
after surgery. The spinal fusion rate was assessed at 6 and 12 months after surgery.
METHODS: The spinal fusion rate and the area of fusion, subsidence of each CaO-SiO2-P2O5-
B2O3 glass ceramics and titanium cage, and the extent of osteolysis were evaluated using a dynamic
plain radiography and a three-dimensional computed tomography at 12 months after surgery. The
present study was supported by BioAlpha, and some authors (JHL, C-KL, and B-SC) have stock
ownership (<10,000 US dollars).
FDA device/drug status: Investigational (NovoMax).
Author disclosures: JHL: Stock Ownership: Bio-alpha (<1%, Other),
outside the submitted work; Grant: BioAlpha Corporation (Work sup-
ported by a Grant-in-Aid), outside the submitted work. C-BK: Nothing to
disclose. JJY: Nothing to disclose. H-JS: Nothing to disclose. K-HK: Grant:
BioAlpha Corporation (Work supported by a Grant-in-Aid), outside the sub-
mitted work. JK: Grant: BioAlpha Corporation (Work supported by a Grant-
in-Aid), outside the submitted work. C-KL: Stock Ownership: BioAlpha (<1%,
Other), outside the submitted work. B-SC: Stock Ownership: BioAlpha (<1%,
Other), outside the submitted work; Grant: BioAlpha Corporation (Work sup-
ported by a Grant-in-Aid), outside the submitted work.
The disclosure key can be found on the Table of Contents and at
www.TheSpineJournalOnline.com.
Institutional Review Board approval was obtained before the study was
started.
* Corresponding author. Department of Orthopedic Surgery, College of
Medicine, Seoul National University, Seoul National University Hospital,
101 Daehakro, Jongnogu, Seoul 110-744, South Korea. Tel.: (82) 2 2072
3864; fax: (82) 2 764 2718.
E-mail address: bschang@snu.ac.kr (B.-S. Chang)
http://dx.doi.org/10.1016/j.spinee.2016.07.531
1529-9430/© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
The Spine Journal 16 (2016) 1367–1376
RESULTS: From the plain radiography results, the 6-month fusion rates for the bioactive glass ce-
ramics group and the titanium group were 89.7% and 91.4%, respectively. In addition, the 12-
month fusion rates based on CT scan were 89.7% and 91.2%, respectively, showing no significant
difference. However, the bone fusion area directly attached to the end plate of either bioactive glass
ceramics or the titanium cage was significantly higher in the bioactive glass ceramics group than in
the titanium group. The ODI, SF-36, back pain, and lower limb pain in both groups significantly
improved after surgery, with no significant differences between the groups. No significant differ-
ences between the two groups were observed in the extent of subsidence and osteolysis.
CONCLUSIONS: In lumbar posterior interbody fusion surgery, CaO-SiO2-P2O5-B2O3 glass ce-
ramics spacer showed a similar fusion rates and clinical outcomes compared with titanium
cage. © 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Clinical trial; Computed tomography; Efficacy; Fusion rate; Glass ceramics; Oswestry Disability Index;
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Introduction
Posterior, posterolateral, or interbody fusion surgery is com-
monly used to prevent postoperative instability from occurring
after nerve decompression surgery in patients with degener-
ative lumbar disease. Posterior lumbar interbody fusion (PLIF),
compared with the posterior or posterolateral fusion method,
demonstrates better stability by directing weight through the
vertebral body in the anterior portion that biomechanically
receives the load [1–3]. In addition, if a cage is used for the
interbody fusion, the cage functions as a spacer to maintain
disc height, preventing intervertebral foraminal stenosis [4].
The most widely used interbody fusion method at the
moment involves the insertion of a titanium or polyether ether
ketone (PEEK) cage filled with autogenous bone into the disc
space after removing a disc. In general, titanium is known
to have more biocompatible properties compared with other
metals and mechanically binds to adjacent bone. However,
titanium is much stronger than bone and may result in sub-
sidence that penetrates into the vertebral end plates without
chemically binding to the bone. Also, although the PEEK cage
is more elastic and radiolucent than titanium, which makes
the progress of bone fusion easier to track, fusion may not
be achieved if the bone inside or around the cage does not
fuse with the end plates, as the PEEK itself does not bind to
the adjacent bone at all.
Bioactive glass ceramics is known to chemically bind to
bone, forming a carbohydroxy apatite layer [5,6]. Na2O-CaO-
SiO2-P2O5 system [7], glass ceramic Ceravital [8], glass
ceramic A–W [5,9], and similar materials were tested, but their
fracture toughness was low. Their Young modulus was also
higher than cortical bone; therefore, they were difficult to insert
into areas that receive loads. The authors of the present study
expected that bioactive glass ceramics, which has high me-
chanical strength and osteoconductivity, developed as a disc
spacer would directly fuse with the bone, obviating the need
to fill the bone, unlike cages. In addition, it would allow better
stability because of the wider contact area with the verte-
bral end plates, and thus possibly reduce subsidence into the
vertebral end plate.
CaO-SiO2-P2O5-B2O3 glass ceramics has been reported to
improve the osteoblastic differentiation of human mesenchy-
mal stem cells [10]. In the in vivo model, the dense cylindrical-
shaped specimen demonstrated better bone bonding to adjacent
bones compared with hydroxyapatite [11] and was found to
improve osseointegration of implants when coating the surface
[12,13]. In addition, CaO-SiO2-P2O5-B2O3 glass ceramics did
not show adverse toxicity effects in a repetitive intravenous
toxicity study [14]. It also demonstrated two times or higher
compressive strength and bending strength compared with hy-
droxyapatite [15].
The authors of the present study produced intervertebral disc
spacers made of CaO-SiO2-P2O5-B2O3 bioactive glass ceramic
materials that fuse directly with bone while maintaining high
strength through finite element modeling for stress distribu-
tion [16]. Furthermore, the authors aimed to evaluate whether
CaO-SiO2-P2O5-B2O3 glass ceramics spacer can replace the cage.
CaO-SiO2-P2O5-B2O3 glass ceramics spacer was implanted in
patients with lumbar degenerative spinal disease who required
one-level PLIF to compare its safety and efficacy, including
clinical results and bone fusion rates, with titanium alloy cages.
Materials and methods
The present study was designed to evaluate whether CaO-
SiO2-P2O5-B2O3 bioactive glass ceramics spacer (NovoMax,
BioAlpha Inc, Seong-nam, Korea) implantation is non-
inferior to a titanium alloy (Ti-6Al-4V) cage (4CIS, Solco
Biomedical, Seoul, Korea) implantation in a PLIF (Fig. 1).
The present study was conducted in consideration of the ethical
issue of using a placebo and was in compliance with the guide-
lines on non-inferiority studies such as the ICH E9 “Statistical
Principles for Clinical Trials” and CPMP/EWP/908/99 “Guide-
line on the Choice of the Non-Inferiority Margin” [17,18].
This prospective study was randomized and single-blinded
(blinded for the patients), and subjects in four institutions were
randomized into either the experimental group (CaO-SiO2-
P2O5-B2O3 bioactive glass ceramics spacer) or the control group
who received a titanium alloy cage. The randomization was
performed with a web-based program and the subjects were
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randomized into the experimental or control groups at a 1:1
ratio. Stratified permuted block randomization was used to
stratify based on age (65 years old or older and less than 65
years old) and instability (spondylolisthesis status).
The inclusion criteria were as follows: (1) patients aged
between 30 and 80; (2) patients who required one-level PLIF
between L1 and S1 among those who required an extensive
laminectomy or facetectomy to correct severe disc extru-
sion or severe spinal stenosis or those who required PLIF due
to grade I or II spondylolisthesis; and (3) those who (only if
a signature was obtainable), or whose legal guardian, fully
understood the clinical trial details and signed the informed
consent form.
The exclusion criteria were as follows: (1) osteoporosis
patients with average T-scores of L1–L4 at <–3.0 in DEXA
bone density tests; (2) women with positive pregnancy tests
before the trial or who planned to become pregnant within
the following 3 years; (3) patients with a history of malig-
nant tumor or malignant diseases (but the cases of cured
disease with no relapse for the past 5 years were included
in the present study); (4) patients with abnormal blood po-
tassium and phosphorus levels; (5) patients with liver disease,
kidney disease, respiratory disease, metabolic disease, or psy-
chological disease; (6) patients deemed to have less than 1-year
life expectancy; (7) patients with mental retardation or whose
parents or legal guardians were older or had mental disabili-
ties; and (8) other patients viewed as inappropriate by the staff.
The estimated number of subjects for the efficacy assess-
ment was 68, 34 for the experimental group and 34 for the
control group (the total number accounting for a 20% dropout
rate was 86 participants). Each institution planned to recruit
at least 12 subjects (6 for the experimental group and 6 for
the control group). To prove non-inferiority on fusion rate for
the CaO-SiO2-P2O5-B2O3 bioactive glass ceramics spacer group
compared with the titanium cage group, the following hy-
potheses was established:
H0: PT–PC≦−δ versus H1: PT–PC>−δ
H0: Null hypothesis
H1: Alternative hypothesis
PT: CaO-SiO2-P2O5-B2O3 bioactive glass ceramics spacer-
group fusion rate
PC: Titanium cage-group fusion rate
−δ: Non-inferior margin 15%
Based on the hypothesis, the number of subjects re-
quired was calculated, and in the event of an equal number
of subjects assigned to each group (1:1) the number of sub-
jects per group was calculated.
The surgery was performed in the same manner as con-
ventional posterior decompression and PLIF. First, the surgical
area was incised to perform laminectomy and facetectomy.
Fig. 1. Gross photographs of implants: (Left) CaO-SiO2-P2O5-B2O3 glass ceramics spacer and (Right) titanium cage.
Context
The authors present results of an industry-sponsored non-
inferiority trial comparing biologically active glass ceramic
interbody devices to titanium cages in the setting of PLIF.
Contribution
Seventy-five patients completed this randomized con-
trolled trial. Raters were not blinded to intervention or
during assessment of fusion rates. No significant differ-
ences were identified between the group treated with
biologic glass and titanium cage based on fusion rate and
clinical outcomes.
Implications
Although this is a randomized trial, there are substantial
concerns given the potential for bias due to industry funding
and lack of blinding with respect to rating of the fusion
rates. As a non-inferiority trial, this study was not de-
signed to detect whether one device was superior to another,
but rather that the devices were sufficiently similar. This
begs the question of cost-effectiveness, as the biologi-
cally active glass is likely more expensive than titanium
cages. In addition, the utility of PLIF over other, less ex-
pensive, forms of fusion-based procedures for a population
such as this also comes into question and this effort is in-
capable of addressing such issues. Lastly, the authors did
not enroll their target number of patients when taking into
account the adjustment for 20% attrition. As it stands, given
these limitations, this study presents Level II evidence at
best.
—The Editors
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A pedicle screw with 6.5-mm diameter and 45- or 40-mm
length was inserted in the lumbar region followed by a sacral
vertebrae with 75-mm diameter and 35-mm or 40-mm length.
A curette and other surgical tools were used to remove the
discs completely, and the soft tissue and cartilage of the end
plates were removed to trim the bone tissue. Then, the local
autogenous bones collected in the decompression process were
broken into fine pieces and inserted into interbody spaces at
10 mL per segment. Two medical devices that fit the inter-
vertebral space used for the test (CaO-SiO2-P2O5-B2O3
bioactive glass ceramics spacer) or the device comparison (ti-
tanium cage) were inserted. In the titanium cage, local bone
was crushed and inserted. During the surgery, the location
of the pedicle screw and the bioactive glass ceramics spacer
or titanium cage was checked, and the rods were connected
to the pedicle screw and tightly fastened. The Hemovac was
then inserted and the area was sutured layer by layer.
The use of bisphosphonate and other bone resorption
inhibitors, systemic adrenocortical hormones, or anabolic
steroids that might affect the efficacy assessment of the
trial was prohibited for 3 months. The use of non-steroidal
anti-inflammatory drugs was not allowed for 1 month, and
parathormone, smoking, and alcohol were also not allowed.
Evaluation
The primary efficacy variable was bone fusion assess-
ment with radiography at 12 months after surgery. The other
variables included bone fusion assessment, assessment of the
area, and proportion of fusion with three-dimensional com-
puted tomography (3D CT) at 12 months after surgery and
bone fusion assessment with radiography at 6 months after
surgery. Oswestry Disability Index (ODI) questionnaire, Short
Form-36 Health Survey (SF-36), visual analog scale (VAS)
pain assessment, subsidence of bioactive glass ceramics spacer
or titanium cage, and the area of fusion with vertebral end
plate were also evaluated. Also, operative time, blood loss,
transfusion rate, and hospital length of stay were evaluated.
The method of assessment was as follows:
Plain radiography
During the subjects’ hospital visits before surgery and also
at 2 weeks and 3 months after surgery, radiography was per-
formed in a standing position to evaluate radiological
abnormalities. At 6 and 12 months after surgery, simple ra-
diological anterior-posterior and lateral, lateral flexion, and
extension images were taken. Fusion was diagnosed when au-
togenous bone in and around the cage or bioactive glass
ceramics spacer was connected to the end plate through bone
trabeculation or was fused to the end plate without a gap, the
fusion segmental angle difference was less than 5°, and the
translation was 3 mm or less [19].
3D CT
3D CT (thin cut, 2-mm interval or under) was performed
at 12 months after surgery. Fusion was diagnosed when the
autogenous bone inside and around the cage or bioactive glass
ceramics spacer was fused to the end plate without a gap or
connected to the end plate through bone trabeculation [20–22].
Four views of CT scan, including sagittal view on the left side,
sagittal view on the right side, coronal view on the left side,
and coronal view on the right side, were evaluated for fusion.
If bony trabeculation between end plates was observed in any
one view out of four views, the segment was diagnosed as a
fused segment.
Independent assessment of plain radiography and 3D CT
The interpretation of the results from plain radiography
and the 3D CT results for bone fusion assessment was per-
formed by two independent evaluators who did not participate
in the clinical trial. The evaluators, without consulting each
other, examined the images on a computer monitor indepen-
dently and assessed the bone fusion. Subject data were
randomly listed regardless of the subject number. Cases as-
sessed as fusion by the two independent evaluators were
accepted as fusion cases. As each segment received either two
cages or bioactive glass ceramics spacer, fusion was defined
when more than one was fused. When there was disagree-
ment between the two evaluators, a third evaluator reviewed
the case of disagreement with the two evaluators and made
a final decision. The extent of osteolysis around the cage or
bioactive glass ceramics spacer and the extent of subsi-
dence of the cage or bioactive glass ceramics spacer into the
vertebral end plate were assessed as a maximum value in 3D
CT sagittal or coronal images.
Oswestry Disability Index assessment
During the subjects’ hospital visits before surgery and at
3, 6, and 12 months after surgery, the ODI questionnaire was
examined. The assessment was calculated as a percentage of
total score compared with scores for answered questions. The
questionnaires that the subject did not answer were excluded.
SF-36
During the hospital visit before surgery and at 3, 6, and
12 months after surgery, the subjects responded to the self-
reported SF-36 survey. The assessment scores were adjusted
based on the original scores for each question item at each
visit. In addition, two summarized sections for physical com-
ponent score (PCS) and mental component score (MCS) were
analyzed separately.
VAS score assessment
The degree of pain perceived by the subjects during ac-
tivity was evaluated using a 100-mm VAS for the low back
and the right and left legs during hospital visits before surgery
and at 3, 6, and 12 months after surgery.
Safety assessment
Safety was assessed through adverse events and clinical
laboratory tests, vital signs, etc. Among the adverse events
related surgery, incidental durotomy, wound infection,
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reoperation, and readmission were compared between ex-
perimental and control groups.
Before surgery and at 2 weeks, 3, 6, and 12 months after
surgery, white blood cell count, red blood cell count, hemo-
globin, hematocrit, platelets, total protein, albumin, aspartate
aminotransferase, alanine aminotransferase, alkaline phos-
phatase, cholesterol, uric acid, creatinine, total bilirubin, blood
urea nitrogen, Ca, P, Na, Cl, glucose, protein, urobilinogen,
ketone, pH, blood pressure, and pulse were measured during
patients’ hospital visits.
Efficacy analysis was performed in those who completed
at least one efficacy assessment on the primary efficacy vari-
able (6 and 12 months x-ray) among those eligible for the
study based on the inclusion and exclusion criteria and who
were randomized into either the experimental or control groups
to receive transplant surgery. For any missing values, the results
measured before the subject’s dropout were imputed as the
value measured after the evaluation point (last observation
carried forward analysis).
Statistical analysis
The fusion rate was calculated for each group and the chi-
square test or Fisher exact test was used to assess the
differences between the groups. Interobserver reliability was
examined with the kappa test. The ODI, SF-36, and VAS for
the experimental and placebo groups were examined with re-
peated measures analysis of variance to examine differences
at 3, 6, and 12 months after surgery compared with the pre-
operative status, as well as the differences in the trend between
the groups. Differences in VAS measured at 3 months, 6
months, and 12 months were adjusted for the baseline level
with the use of analysis of covariance. In addition, at each
postoperative time point, the intra- and intergroup differ-
ences were compared more specifically with the paired t test
and unpaired t test. The significance level was adjusted in terms
of test multiplicity. To adjust other factors that may affect the
results, the general mixed model was used to assess the sig-
nificance level of the group-to-group differences.
Results
Baseline characteristics
Eighty-six subjects were randomly allocated: 80 patients
(93.0%; 41 in the experimental group, 39 in the control group)
received medical devices and 75 patients (87.2%; 39 in the
experimental group, 36 in the control group) completed the
clinical study. One subject who did not complete a safety eval-
uation was excluded. Thus, 79 patients remained in the safety
analysis group. Of these patients, 74 were remained for ef-
ficacy analysis (Fig. 2).
No significant intergroup differences were found on the
average age, gender, average weight, history of smoking, pre-
operative diagnosis, and bone mineral density (Table 1). There
were no significant differences between the experimental group
and the control group in the ODI, VAS scores for both legs,
SF-36 eight scales, and SF-36 two summaries (Table 2).
However, whereas the total VAS score for low back was
51.9±30.2 points, the score for the experimental group was
59.6±28.0 and the control group had a score of 43.3±30.6,
showing statistically significant intergroup difference
(p=.0196).
Bone fusion assessment results from plain radiography
In the plain radiography results (Fig. 3) for the efficacy
analysis population, the fusion rate at 6 months was 89.7%
Fig. 2. Flow diagram of the study.
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(35 subjects) for the experimental group and 91.4% (32 sub-
jects) for the control group, showing no significant intergroup
difference (Table 3). Interobserver reliability was ranged from
0.66 to 1.00 kappa value in each of the fusion criteria. The
fusion rate at 12 months was 89.7% (35 subjects) for the ex-
perimental group and 91.4% (32 subjects) for the control
group; there was no significant intergroup difference.
Interobserver reliability ranged from 0.793 to 1.00 kappa value
in each of the fusion criteria.
Bone fusion assessment results from 3D CT
In the 3D CT (Fig. 4), the fusion rate at 12 months was
89.7% (35 subjects) for the experimental group and 91.2%
(31 subjects) for the control group, showing no significant
difference between groups (Table 4). Interobserver
reliability ranged from 0.564 to 0.787 kappa value in each
CT view.
Osteolysis and end plate subsidence assessment results
from 3D CT
Osteolysis was 7.7% in the experimental group and
5.9% in the control group with no significant intergroup
difference.
End plate subsidence in the experimental and control groups
was 1.10 mm (±0.99) and 0.94 mm (±0.73), respectively, with
no significant intergroup difference. However, the experi-
mental group showed significantly higher upper end plate
subsidence (1.39±1.21) than lower end plate subsidence
(0.80±0.55) (p=.0001), whereas the control group had no sig-
nificant difference between the upper end plate (1.01±0.68)
and the lower end plate subsidence (0.88±0.77).
Table 1
Summary of demographic characteristics (efficacy analysis population)
Experimental
group
(N=39)
Control
group
(N=35) p-Value
Age (y) mean±SD 61.5±9.4 61.1±8.3 .8573*
Sex (female), n (%) 27 (69.2) 21 (60.0) .4063†
Weight (kg) mean±SD 63.5±8.6 66.2±10.6 .220*
Smoking, n (%) .826‡
Currently smoking 4 (10.3) 2 (5.7)
Quit smoking 4 (10.3) 4 (11.4)
Never smoked 31 (79.5) 29 (82.9)
Drinking, n (%) .2783‡
Currently drinking 13 (33.3) 7 (20.0)
Quit drinking 1 (2.6) 3 (8.6)
Never drank 25 (64.1) 25 (71.4)
Preoperative diagnosis, n (%)
Herniated intervertebral disc 6 (15.4) 4 (11.4) .7398‡
Spinal stenosis 24 (61.5) 19 (54.3) .5278†
Minor to moderate
spondylolisthesis
18 (46.2) 16 (45.7) .9698†
Spondylolysis 4 (10.3) 2 (5.7) .6771‡
Bone mineral density .4288*
(T-score) mean±SD −0.26±1.3 −0.50±1.2
SD, standard deviation.
Percentages are based on N.
* p-Value from unpaired t test (difference between treatment groups).
† p-Value from chi-square test (difference between treatment groups).
‡ p-Value from Fisher exact test (difference between treatment groups).
Fig. 3. Plain radiographs: (Left) CaO-SiO2-P2O5-B2O3 glass ceramics spacer and (Right) titanium cage.
Table 2
Summary of other characteristics at screening
Experimental
group (N=39)
Control group
(N=35) p-Value*
(Mean±SD)
ODI 51.2±16.6 44.7±15.0 .0845
VAS (lower back) 59.6±28.0 43.3±30.6 .0196
VAS (left leg) 49.6±36.4 52.2±35.0 .7591
VAS (right leg) 48.5±36.1 50.6±32.6 .7931
SF-36 eight scales
Physical functioning 37.8±20.0 44.2±24.2 .2173
Mental health 52.7±16.0 56.7±25.6 .4304
General health 50.9±15.3 53.8±16.19 .4314
Bodily pain 31.2±20.5 35.1±18.1 .3800
Role-physical 35.4±22.4 38.4±27.6 .6105
Role-emotional 45.5±28.8 52.6±29.6 .2992
Social functioning 58.7±23.5 58.9±29.0 .9643
Vitality 40.1±18.3 39.1±23.9 .8464
SF-36 two summary measures
Physical component score 38.8±15.6 42.9±14.8 .2570
Mental component score 49.2±16.5 51.8±21.7 .5603
SD, standard deviation; ODI, Oswestry Disability Index; VAS, visual
analog scale; SF-36, Short Form-36 Health Survey.
* p-Value from unpaired t test (difference between treatment groups).
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ODI results
The ODI of the experimental group was 51.2±16.6 before
surgery, 33.3±14.9 at 3 months after surgery, 31.9±14.9 at 6
months after surgery, and 27.9±17.6 at 12 months after surgery,
which showed significant reduction at each time point from
the baseline status (p<.0001 in all cases) (Table 5).
In the control group, the ODI was 44.7±15.0 before surgery
and decreased to 29.5±14.7 at 3 months after surgery,
29.1±16.2 at 6 months after surgery, and 23.1±16.2 at 12
months after surgery, showing a statistically significant dif-
ference at all time points compared with the baseline status
(p<.0001 in all cases). When intergroup difference factors
related to institution and gender were adjusted, no statisti-
cal significance was found (p=.7490).
SF-36 results
In the SF-36 survey, the PCS evaluation results for the ex-
perimental group and the control group showed statistically
significant increases at 3, 6, and 12 months after surgery com-
pared with before surgery, indicating an improvement in PCS
(p<.0001 for all cases in the experimental group; p<.0046,
p<.0001, and p<.0001 for the control group) (Table 6). When
intergroup difference factors related to institution and gender
were adjusted, no statistical significance was found.
Also, the MCS evaluation results for the experimental and
control groups showed statistically significant increases com-
pared with before surgery at 3, 6, and 12 months after surgery,
indicating an improvement in MCS (p<.0001 for all cases in
the experimental group; p=.0023, p<.0001, and p<.0001 for
the control group). When intergroup difference factors related
to institution and gender were adjusted, no statistical signif-
icance was found.
For bodily pain evaluations, the experimental and control
groups showed statistically significant increases at each time
point measured, ie, at 3, 6, and 12 months after surgery, com-
pared with the values measured before surgery, indicating
improvement in bodily pain (p<.0001 for all cases in the
Table 3
Radiographic fusion rates when fusion is defined as bone bridging or seg-
mental angle difference <5° and translation ≤3 mm (%)
Experimental group
(N=39)
Control
group
(N=35)
6 Months
Fusion, n (%) 35 (89.7) 32 (91.4)
p-Value* 1.0000
Interobserver reliability (kappa value with p-value)
Bone bridging 0.926 (p-value<.001)
Segmental angle difference less
than 5°
1.000 (p-value<.001)
Translation less than 3 mm 0.660 (p-value<.001)
12 Months
Fusion, n (%) 35 (89.7) 32 (91.4)
Interobserver reliability (kappa value with p-value)
Bone bridging 0.916 (p-value<.001)
Segmental angle difference less
than 5°
0.793 (p-value<.001)
Translation less than 3 mm 0.850 (p-value<.001)
Percentages are based on N.
* p-Value from chi-square test (difference between treatment groups).
Fig. 4. Three-dimensional computed tomography: (Left) CaO-SiO2-P2O5-B2O3 glass ceramics spacer and (Right) titanium cage.
Table 4
CT fusion rates (%) at 12 months
Experimental group
Control
group
12 Months, N 39 34
Fusion, n (%) 35 (89.7) 31 (91.2)
p-value* 1.0000
Interobserver reliability (kappa value with p-value)
Sagittal view on the left side 0.564 (p-value<.001)
Sagittal view on the right side 0.571 (p-value<.001)
Coronal view on the left side 0.770 (p-value<.001)
Coronal view on the right side 0.787 (p-value<.001)
CT, computed tomography.
Percentages are based on N.
* p-Value from Fisher exact test (difference between treatment groups).
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experimental and control groups). In addition, when inter-
group difference factors related to institution and gender were
adjusted, no statistical significance was found.
VAS results
The VAS low back pain evaluation showed significant re-
duction in the pain score at 3, 6, and 12 months after surgery
compared with before surgery, indicating that the degree of
pain was decreased (p<.0001 in all cases in the experimen-
tal group; p=.0015, p=.0012, and p=.0002 in the control group).
There was no significant intergroup difference in VAS at
3 months (p=.7530), 6 months (p=.9518), and 12 months
(p=.3949) after adjustment for baseline differences with the
use of analysis of covariance (Table 7).
In the VAS left and right leg pain evaluation, the exper-
imental group and the control group showed significant
decreases in pain levels at 3, 6, and 12 months after surgery
compared with before surgery, indicating the reduction of
pain (p<.001 in all cases in the experimental and control
groups). When intergroup difference factors on institution and
gender were adjusted, no statistical significance was found
(Table 8).
Adverse events
The numbers of subjects who experienced at least one
adverse event in the experimental and control groups were
35 (87.5%) and 37 (94.9%), respectively. A total of 155 in-
cidents were recorded in the experimental group and 132
occurred in the control group, resulting in no significant in-
tergroup difference (p=.4315). Serious adverse events occurred
in three subjects (four cases); two were in the experimental
group (two cases) and one was in the control group (two cases).
In the experimental group, although one subject experi-
enced back pain caused by osteolysis and a non-union, pedicle
screw fracture, the symptoms improved and the subject was
followed for further observation without surgical interven-
tion. The other subject in the experimental group developed
acute pyelonephritis, whereas the subject in the control group
developed hematochezia. However, both subjects recovered
and the events were not related to the medical devices. There
were some items in vital signs and clinical laboratory test
results that showed significant differences in intragroup or in-
Table 5
Summary of Oswestry Disability Index (score) by visit
Experimental group (N=39) Control group (N=35) Change from screening
Mean±SD Experimental group Control group Total
Preoperative 51.2±16.6 44.7±15.0
3 Months 33.3±14.9 29.5±14.7 −17.6±17.3 −15.2±16.8 −16.6±17.0
p-Value <.0001* <.0001* .5053†
6 Months 31.9±14.9 29.1±16.2 −19.3±15.3 −15.8±17.1 −17.6±16.2
p-Value <.0001* <.0001* .3370†
12 Months 27.9±17.6 23.2±16.2 −23.3±19.5 −21.6±16.9 −22.5±18.2
p-Value <.0001* <.0001* .6813†
p-Value‡ .7490
SD, standard deviation.
* p-Value from paired t test.
† p-Value from unpaired t test.
‡ p-Value from general mixed model after adjusting site and sex.
Table 6
Summary of SF-36 (score) summary measures: physical component score
and mental component score
Experimental
group (N=39)
Control
group
(N=35) Change from screening
Mean±SD
Experimental
group
Control
group
Physical component score
Preoperative 38.8±15.6 42.9±14.8
3 Months 51.8±17.3 53.5±20.2 13.0±13.9 10.6±20.6
p-Value <.0001* .0046*
6 Months 56.8±19.3 61.5±17.5 17.9±18.0 18.6±17.8
p-Value <.0001* <.0001*
12 Months 62.7±18.5 68.5±18.6 23.9±13.6 25.6±18.4
p-Value <.0001* <.0001*
Mental component score
Preoperative 49.2±16.5 51.8±21.7
3 Months 64.4±21.7 62.8±24.3 15.2±17.7 10.9±19.6
p-Value <.0001* .0023*
6 Months 63.9±19.3 68.7±20.6 14.7±17.2 16.8±20.7
p-Value <.0001* <.0001*
12 Months 69.5±19.7 75.6±18.2 20.3±19.3 24.0±22.1
p-Value <.0001* <.0001*
SD, standard deviation; SF-36, Short Form-36 Health Survey.
* p-Value from paired t test.
Table 7
Summary of VAS (score) of lower back
Experimental
group (N=39)
Control
group (N=35) p-Value*
Baseline 59.6±28.0 43.3±30.6 p=.0196
3 Months 27.8±23.0 25.6±24.2 p=.7530
6 Months 29.5±23.7 25.2±22.6 p=.9518
12 Months 19.6±18.5 21.1±20.9 p=.3949
VAS, visual analog scale.
* p-Value from adjusted difference by analysis of covariance.
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tergroup analysis; however, the changes were within the normal
range and were not clinically meaningful.
There were no significant differences between the two
groups in terms of operative time, blood loss, transfusion
amount, and hospital length of stay. Also, the incidental
durotomy showed no significant differences between the
groups, and wound infection, reoperation, and readmission
did not occur in both groups (Table 9).
Discussion
The role of a cage or intervertebral spacer in PLIF surgery
is to prevent foraminal stenosis [23] by maintaining inter-
vertebral stability at the initial stage of insertion [24],
facilitating intervertebral fusion, and maintaining disc height
[24,25]. In the present study, the authors aimed to compare
the efficacy and safety of CaO-SiO2-P2O5-B2O3 glass ceram-
ics spacer, including radiological and clinical results, with those
of the titanium cage when inserted between L1 and S1 in pa-
tients with lumbar degenerative disease who required one-
level PLIF. The most frequently used cage materials so far
are titanium and PEEK. The use of these materials have been
shown to provide more satisfactory results in terms of a high
fusion rate and load sharing in the vertebral body compared
with posterolateral fusion surgery. Although the PEEK cage
allows for assessing the level of fusion using plain radio-
graph, the titanium cage had a similar level of mechanical
strength as CaO-SiO2-P2O5-B2O3 glass ceramics. Both the ti-
tanium and PEEK cages resulted in a higher fusion rate than
posterolateral fusion surgery. Therefore, it was deemed rea-
sonable to design the present study to prove the non-inferiority
of CaO-SiO2-P2O5-B2O3 glass ceramics spacer compared with
the titanium cage.
In the clinical results, both groups showed significant im-
provement after surgery in terms of back pain and radiating
pain, ODI, SF-36, etc compared with the preoperative status,
with no significant intergroup differences.
Among the properties of intervertebral spacers, compres-
sive strength and bending strength are important factors for
a successful surgery because these are related to damage during
surgery and long-term repetitive load bearing. In the case of
a hydroxyapatite spacer used previously, damage during the
surgical process because of its weak mechanical strength was
reported. CaO-SiO2-P2O5-B2O3 glass ceramics, however, is
known to have at least 2.5 times more compressive strength
than hydroxyapatite spacers [15]. In the compressive strength
analysis of the same size of CaO-SiO2-P2O5-B2O3 glass
ceramics, titanium and PEEK cages, CaO-SiO2-P2O5-B2O3 glass
ceramics showed 4 times and 1.3 times higher strength than
PEEK cage and titanium cage, respectively. In this study, no
damage was observed during the surgery or the 1-year follow-
up observation. Therefore, it was determined that the risk of
damage similar to the conventional hydroxyapatite spacer was
alleviated. However, the increased mechanical strength of CaO-
SiO2-P2O5-B2O3 glass ceramics results in a higher risk of
subsidence in patients with osteoporosis. Moreover, if only
CaO-SiO2-P2O5-B2O3 glass ceramics is used for vertebral end
plate fusion without local autobone, subsidence may occur.
In the comparison of subsidence with the titanium cage, both
groups showed no difference. This could be interpreted as the
mechanical strength of CaO-SiO2-P2O5-B2O3 glass ceramics
having an insignificant effect on subsidence or the stress dis-
tribution preventing subsidence because of the large fusion
area between NovoMax and the end plates.
As CaO-SiO2-P2O5-B2O3 glass ceramics is a new materi-
al, and its safe use is critical. Studies on repetitive toxicity
have reported that high-dose intravenous injections of aqueous
extracts from CaO-SiO2-P2O5-B2O3 glass ceramics for 90 days
showed no special adverse reaction [14]. CaO-SiO2-P2O5-
B2O3 glass ceramics has a very low bioabsorbability because
the fast resorption of glass ceramics negatively affects its
role as an osteoconductive scaffold [26]. In addition,
Table 8
Summary of VAS (score) of leg pain
Experimental
group (N=39)
Control
group
(N=35) Change from screening
Mean±SD
Experimental
group
Control
group
Left
Preoperative 49.6±36.4 52.2±35.0
N 39 35
3 Months 17.8±25.7 19.6±25.7 −31.9±41.0 −32.6±32.2
p-Value <.0001* <.0001*
6 Months 20.6±23.9 15.8±21.0 −29.1±37.3 −36.4±35.3
p-Value <.0001* <.0001*
12 Months 14.7±24.5 18.4±24.7 −35.0±43.9 −33.8±36.6
p-Value <.0001* <.0001*
Right
Preoperative 48.5±36.1 50.6±32.6
N 39 35
3 Months 26.3±31.5 16.3±23.8 −22.2±36.4 −34.4±39.1
p-Value .0005* <.0001*
6 Months 20.6±23.4 10.4±16.1 −28.0±35.3 −40.2±34.8
p-Value <.0001* <.0001*
12 Months 20.9±26.7 17.6±23.9 −27.6±37.8 −33.0±36.7
p-Value <.0001* <.0001*
VAS, visual analog scale; SD, standard deviation.
* p-Value from paired t test.
Table 9
Summary of surgical results and adverse events (efficacy analysis population)
Experimental
group (N=39)
Control
group
(N=35) p-Value
Hospital stay (d) mean±SD 9.9±3.2 10.7±3.2 .294
Operative time (min) mean±SD 154.7±31.6 161.3±37.4 .392
Blood loss (mL) mean±SD 434±244 492±243 .285
Transfusion (packs) mean±SD 0.25±0.71 0.55±1.0 .128
Rate of durotomy (%) 7.3 4.9 1.0
Rate of wound infection (%) 0 0 1.0
Rate of reoperation (%) 0 0 1.0
Rate of readmission (%) 0 0 1.0
SD, standard deviation.
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CaO-SiO2-P2O5-B2O3 glass ceramics is surrounded by bony
tissues or fibrous tissues due to the interbody fusion, further
reducing the possibility that the inserted CaO-SiO2-P2O5-
B2O3 glass ceramics will be reabsorbed. Therefore, it is
expected that the possibility of adverse tissue reaction or sys-
temic reaction is extremely low even if CaO-SiO2-P2O5-
B2O3 glass ceramics remains in the body for a long period.
In the safety assessment results from the present study, adverse
events attributed to the medical devices were observed in only
one person in the experimental group, and it was back pain
due to osteolysis, pseudarthrosis, and pedicle screw break-
age. Severe adverse events totaled 5% in the experimental
group and 2.6% in the control group, and the intergroup dif-
ference was not statistically significant. Although no special
adverse events were found during the 1-year follow-up, longer
follow-up observation is necessary given the material’s long-
term existence in the body.
The limitation of this research is that the fusion methods
and the amount of autologous bone graft used in the present
study are not identical to the ones in clinical practice. Usually
in clinical practice, all available local bone is used along with
allograft or artificial bone graft if necessary. Also, facet fusion
or intertransverse process fusion is often performed togeth-
er with interbody fusion. However, for fair comparison between
two groups, the present study used only 10 mL of local bone
and performed interbody fusion alone.
Overall, this clinical trial showed that CaO-SiO2-P2O5-
B2O3 glass ceramics had a similar fusion rates and clinical
outcomes as titanium cages for patients with degenerative
lumbar disease who required one-level PLIF operation and
showed negligible abnormal responses.
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